Lifecore Biomedical Agrees to Be Acquired by Warburg Pincus for $17.00 Per Share in Cash
15 Enero 2008 - 4:30AM
Business Wire
LIFECORE BIOMEDICAL, INC. (NASDAQ:LCBM) announced today that it has
entered into a definitive agreement with affiliates of Warburg
Pincus, the global private equity firm, to be acquired through a
tender offer, followed by a merger, for a price of $17.00 per share
in cash. The transaction, valued at approximately $239 million, is
subject to the valid tender of a majority of Lifecore Biomedical�s
fully diluted common shares, regulatory approvals and other
customary conditions, but is not subject to any financing
condition. The $17.00 per share price represents a premium of
approximately 30% over the volume weighted average price of
Lifecore Biomedical�s shares for the last 30 trading days. Lifecore
Biomedical expects the transaction to close by the end of the first
quarter of 2008. Lifecore Biomedical�s Board of Directors has
unanimously approved the definitive agreement and has resolved to
recommend that Lifecore Biomedical�s shareholders tender their
shares in connection with the tender offer contemplated by the
definitive agreement. �In addition to our shareholders, who we
believe will receive fair value for their Lifecore shares, we
believe that this transaction with Warburg Pincus is positive for
our employees and our customers,� said Dennis J. Allingham,
President and CEO of Lifecore Biomedical. �The transaction will
allow us to continue to provide exceptional products to our
customers. As a private company, Lifecore will have greater
flexibility to focus on its long-term strategic direction. Warburg
Pincus and its affiliates have confidence in Lifecore�s future and
will support achieving our long-term goals.� Lifecore Biomedical
intends to solicit superior proposals from third parties during the
next 30 calendar days, as permitted by, and subject to, the terms
of the definitive agreement. There can be no assurance that the
solicitation of superior proposals will result in an alternative
transaction. Lifecore does not intend to disclose developments with
respect to this solicitation process unless and until its Board of
Directors has made a decision regarding any alternative proposals.
Piper Jaffray & Co. is acting as financial advisor and Dorsey
& Whitney LLP is acting as legal counsel to Lifecore. Willkie
Farr & Gallagher LLP is acting as legal advisor to Warburg
Pincus. About Lifecore Biomedical Lifecore Biomedical, in business
over 40 years, develops, manufactures and markets biomaterials and
medical devices for use in various surgical markets through two
divisions, the Dental Division and the Hyaluronan Division. The
Dental Division conducts its dental surgery business through direct
sales and marketing in the United States, France, Germany, Italy
and Sweden and through distributors in 49 other countries. The
Hyaluronan Division conducts its business through OEM and contract
manufacturing alliances in the ophthalmic, orthopedic and
veterinary surgical fields. News and general information are
available through the Company�s website at www.lifecore.com. About
Warburg Pincus Warburg Pincus has been a leading private equity
investor since 1971. The firm currently has approximately $20
billion of assets under management with an additional $10 billion
available for investment. Since inception, Warburg Pincus has
invested $29 billion in 585 companies in 30 countries and across a
range of sectors, including healthcare, consumer and retail,
industrial, financial services, energy, real estate and technology,
media and telecommunications. The firm has invested $6.2 billion in
healthcare-related companies around the world, including
approximately $2.7 billion in medical devices. Notable medical
device investments include: American Medical Systems (Nasdaq:AMMD),
Bausch & Lomb, ev3 (Nasdaq:EVVV), Kyphon (acquired by Medtronic
in 2007), Tornier, and Wright Medical Group (Nasdaq:WMGI). Warburg
Pincus has offices in Beijing, Frankfurt, Hong Kong, London, San
Francisco, Mumbai, New York, Shanghai, and Tokyo. For more
information please visit www.warburgpincus.com. Conference Call
Lifecore Biomedical will host a conference call today at 7:00 a.m.
Central Time to discuss the transaction and fiscal 2008 second
quarter results. Investors interested in participating in the live
call can dial (800) 896-8445 from the U.S. International callers
can dial (785) 830-1916. A telephone replay will be available
approximately two hours after the call concludes and will be
available through Tuesday, January 22, 2008, by dialing (888)
203-1112 from the U.S., or (719) 457-0820 for international callers
and entering confirmation code 2333334. There also will be a
simultaneous webcast available on the Investor Relations section of
the Company's web site at www.lifecore.com. For those unable to
participate during the live broadcast, the webcast will be archived
for 30 days. The webcast is also being distributed over
THOMSON/CCBN's Investor Distribution Network. Individual investors
can listen to the call through THOMSON/CCBN's individual investor
center at www.earnings.com Institutional investors can access the
call via StreetEvents www.streetevents.com. The conference call may
include forward-looking statements. See the cautionary information
about such statements in the �Forward Looking Statements� section
below. Forward Looking Statements This news release contains, among
other things, certain statements of a forward-looking nature. Such
statements include all statements other than those made solely with
respect to historical fact. Numerous risks, uncertainties and other
factors may cause actual results to differ materially from those
expressed in any forward-looking statement. These factors include,
but are not limited to, (1) the occurrence of any event, change or
other circumstance that could give rise to the termination of the
definitive agreement; (2) the outcome of any legal proceedings that
may be instituted against the Company and others following the
announcement of the transaction; (3) the inability to complete the
transaction due to the failure to satisfy the conditions thereto;
(4) the proposed transaction may disrupt current plans and
operations and the potential difficulties in employee retention as
a result of the announcement of the transaction; and (5) other
factors described in the Company�s filings with the Securities and
Exchange Commission, including its reports on Forms 10-K, 10-Q, and
8-K. Many of the factors that will determine the outcome of the
subject matter of this communication are beyond the Company�s
ability to control or predict. The Company undertakes no obligation
to revise or update any forward-looking statements, or to make any
other forward-looking statements, whether as a result of new
information, future results or otherwise. Important Notice This
press release is for informational purposes only and is not an
offer to buy or the solicitation of an offer to sell any of
Lifecore�s common shares. The tender offer described herein has not
yet been commenced. On the commencement date of the tender offer,
an offer to purchase, a letter of transmittal and related documents
will be filed with the Securities and Exchange Commission, will be
mailed to shareholders of record and will also be made available
for distribution to beneficial owners of common shares. The
solicitation of offers to buy Lifecore common shares will only be
made pursuant to the offer to purchase, the letter of transmittal
and related documents. When they are available, shareholders should
read those materials carefully because they will contain important
information, including the various terms of, and conditions to, the
tender offer. When they are available, shareholders will be able to
obtain the offer to purchase, the letter of transmittal and related
documents without charge from the Securities and Exchange
Commission's Website at www.sec.gov or from the information agent
that we select. Shareholders are urged to read carefully those
materials when they become available prior to making any decisions
with respect to the tender offer. Lifecore will file a
solicitation/recommendation statement with the SEC in connection
with the tender offer, and, if required, will file a proxy
statement or information statement with the SEC in connection with
the second-step merger. Shareholders are strongly advised to read
these documents if and when they become available because they will
contain important information about the tender offer and the
proposed merger. Shareholders would be able to obtain a free copy
of the solicitation/recommendation statement and the proxy
statement or information statement as well as other filings
containing information about Lifecore, the tender offer and the
merger, if and when available, without charge, at the SEC's
Internet site www.sec.gov. In addition, copies of the
solicitation/recommendation statement, the proxy statement or
information statement and other filings containing information
about Lifecore, the tender offer and the merger may be obtained, if
and when available, without charge, by directing a request to
Lifecore, Attention: Dennis J. Allingham, President and Chief
Executive Officer, 3515 Lyman Boulevard, Chaska, Minnesota 55318,
by phone at 952.368.4300, or on Lifecore�s Internet site at
www.lifecore.com.
Lifecore Biomedical (MM) (NASDAQ:LCBM)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Lifecore Biomedical (MM) (NASDAQ:LCBM)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024